Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-08-14 , DOI: 10.1111/apt.18213
Chan-Young Jung ₁ , Jung Il Lee _{2,

3} , Sang Hoon Ahn _{3,

4} , Seung Up Kim _{3,

4} , Beom Seok Kim ₅

Affiliation

Despite the development of transient elastography (TE)-based Agile scores for diagnosing fibrotic burden in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), their applicability in predicting kidney outcomes remains unclear. We aimed to investigate the association between liver fibrotic burden, as assessed by Agile scores, and the risk of incident chronic kidney disease (CKD) in patients with MASLD.

中文翻译：

Agile 3+ 和 Agile 4 评分可预测代谢功能障碍相关脂肪肝病中慢性肾病的发展

尽管开发了基于瞬时弹性成像 (TE) 的 Agile 评分来诊断代谢功能障碍相关脂肪肝病 (MASLD) 患者的纤维化负担，但它们在预测肾脏结局方面的适用性仍不清楚。我们的目的是调查通过 Agile 评分评估的肝纤维化负担与 MASLD 患者发生慢性肾脏病 (CKD) 的风险之间的关联。

更新日期：2024-08-14

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南